Online inquiry

IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ848MR)

This product GTTS-WQ848MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD276 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001024736.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 80381
UniProt ID Q5ZPR3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ848MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9012MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ15219MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ3723MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ4373MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-188667
GTTS-WQ5870MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CIFN
GTTS-WQ8084MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ11899MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MLN-1202
GTTS-WQ6568MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DC-1630423
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW